OKUR OnKure Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1637715 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.5%
TTM EPS YoY-102.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.2%
ROA-51.6%
ROIC (approx.)-4,360.7%
Asset turnover—
Leverage & solvency
Liabilities / assets5.6%
Debt / equity0.00x
Current ratio18.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $15.06M | $12.61M | $11.71M | $10.72M | $11.91M | $12.61M | $13.01M | $37.36M |
| SG&A expense | $4.29M | $4.29M | $3.91M | $3.40M | $3.59M | $3.71M | $3.99M | -$3.56M |
| Operating income | -$19.35M | -$16.90M | -$15.62M | -$14.12M | -$15.50M | -$16.32M | -$17.00M | -$33.80M |
| Net income | -$17.85M | -$15.35M | -$15.16M | -$13.50M | -$14.70M | -$15.39M | -$15.93M | -$17.44M |
| EBITDA | -$19.30M | -$16.81M | -$15.51M | -$14.02M | -$15.39M | -$16.21M | -$16.88M | -$33.38M |
| EPS (basic) | -0.36 | -0.31 | -1.11 | — | -1.09 | -1.14 | -1.19 | — |
| EPS (diluted) | -0.36 | -0.31 | -1.11 | — | -1.09 | -1.14 | -1.19 | — |
| Weighted avg. shares (diluted) | 49.93M | 49.87M | 13.67M | — | 13.53M | 13.51M | 13.42M | — |
| Banking | ||||||||
| Net interest income | $1.50M | $1.55M | $458,000 | $622,000 | $802,000 | $934,000 | $1.07M | $1.26M |
| Balance sheet | ||||||||
| Cash & equivalents | $151.44M | $166.50M | $192.11M | $59.05M | $70.33M | $83.37M | $96.66M | $110.76M |
| Short-term investments | $11.86M | $9.88M | — | $0 | — | — | — | — |
| Current assets | $165.59M | $177.68M | $197.48M | $60.84M | $71.53M | $84.55M | $98.17M | $113.00M |
| PP&E, net | $414,000 | $435,000 | $519,000 | $618,000 | $720,000 | $821,000 | $925,000 | $1.02M |
| Total assets | $167.08M | $179.35M | $198.69M | $62.12M | $72.83M | $86.07M | $99.88M | $114.91M |
| Current liabilities | $8.79M | $6.64M | $14.33M | $5.92M | $6.25M | $7.60M | $8.79M | $10.53M |
| Total liabilities | $9.34M | $7.25M | $14.34M | $5.93M | $6.41M | $7.90M | $9.23M | $11.08M |
| Shareholders' equity | $157.74M | $172.11M | $184.35M | $56.18M | $66.43M | $78.17M | $90.65M | $103.83M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.08M | -$10.35M | -$12.94M | -$11.51M | -$13.04M | -$13.27M | -$14.01M | -$21.02M |
| Capital expenditure | $32,000 | $3,000 | $5,000 | $9,000 | $6,000 | $13,000 | $18,000 | $50,000 |
| Free cash flow | -$13.11M | -$10.36M | -$12.94M | -$11.52M | -$13.04M | -$13.29M | -$14.02M | -$21.07M |
| Investing cash flow | -$1.97M | -$9.87M | -$5,000 | -$9,000 | -$6,000 | -$13,000 | -$18,000 | -$45.38M |
| Financing cash flow | -$8,000 | -$5.38M | $146.00M | $240,000 | $0 | $0 | -$77,000 | $114.22M |
| Depreciation & amortization | $53,000 | $87,000 | $104,000 | $104,000 | $108,000 | $117,000 | $118,000 | $419,000 |
| Stock-based compensation | $3.49M | $3.05M | $2.78M | $3.02M | $2.96M | $2.91M | $2.75M | $1.64M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.